Integrated Biosciences introduced a novel optogenetic screening platform enabling precise modulation of biological pathways with light. Applying this technology, the company screened over 370,000 compounds targeting the integrated stress response (ISR), identifying several ISR-potentiating small molecules that sensitize stressed cells to apoptosis without cytotoxicity. One compound demonstrated broad antiviral activity and reduced viral pathology in mouse models. Published in Cell, this platform combines optogenetics, chemistry, and AI to facilitate unprecedented pathway-specific drug discovery relevant to age-related diseases.